PROCEPT BioRobotics

At face value, PROCEPT BioRobotics Corp looks inexpensive, following a substantial price decline over the past year. To account for the risk of a possible value trap, we have capped its rating at 3 stars. The stock currently trades at a 36% discount to our quantitative fair value estimate of $27.95 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's solid growth strengthens our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its revenue 5-year growth of 62.5%, which lies in the top 10% compared with global peers. Relatively strong trailing five-year revenue growth suggests a compelling trajectory for future sales and earnings, which contributes to our view that shares are cheap.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 4.3, for example, ranks in the bottom 40% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. This characteristic further promotes our favorable price/fair value ratio.

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.